164 related articles for article (PubMed ID: 26474569)
1. A case of simultaneous occurrence of acute myeloid leukemia and multiple myeloma.
Lu-Qun W; Hao L; Xiang-Xin L; Fang-Lin L; Ling-Ling W; Xue-Liang C; Ming H
BMC Cancer; 2015 Oct; 15():724. PubMed ID: 26474569
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia.
Lei M; Liu L; Wang Z; Wu D
Indian J Cancer; 2019; 56(2):167-172. PubMed ID: 31062738
[TBL] [Abstract][Full Text] [Related]
3. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
[TBL] [Abstract][Full Text] [Related]
4. Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.
Qu Q; Liu L; Zhang Y; Li X; Wu D
Leuk Res; 2015 Dec; 39(12):1353-9. PubMed ID: 26432074
[TBL] [Abstract][Full Text] [Related]
5. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
[TBL] [Abstract][Full Text] [Related]
6. [Complete remission achieved by low-dose Ara-C, aclarubicin and rhG-CSF (CAG) therapy in acute non-lymphocytic leukemia with monosomy 7 occurring after severe aplastic anemia].
Yamato H; Yamada K; Koike T; Yoshida M; Tsunogake S; Aoyagi M; Nakamura Y; Watanabe K; Saito K; Enokihara H
Rinsho Ketsueki; 1995 Feb; 36(2):128-33. PubMed ID: 7536277
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic effect of priming induction regimen of CAG for newly diagnosed acute myeloid leukemia in elderly patients].
Chen YJ; Zhang LQ; Li XL; Zhao XL; Wu DS; Shu YG; Chen FP
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Mar; 33(3):245-51. PubMed ID: 18382060
[TBL] [Abstract][Full Text] [Related]
8. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
Minakata D; Fujiwara S; Ito S; Mashima K; Umino K; Nakano H; Kawasaki Y; Sugimoto M; Yamasaki R; Yamamoto C; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
Leuk Res; 2016 Mar; 42():82-7. PubMed ID: 26790727
[TBL] [Abstract][Full Text] [Related]
9. [Low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor for the treatment of relapsed acute myeloid leukemia].
Saito K
Rinsho Ketsueki; 1996 Aug; 37(8):651-3. PubMed ID: 8827872
[TBL] [Abstract][Full Text] [Related]
10. Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21).
Wang Y; Li W; Chen S; Qiu H; Sun A; Wu D
Leuk Res; 2011 May; 35(5):604-7. PubMed ID: 21130493
[TBL] [Abstract][Full Text] [Related]
11. [Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in 50 patients with relapsed acute myeloid leukemia].
Zhu BG; Qian SX; Hong M; Lu H; Wu HX; Zhang SJ; Qiu HX; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):760-4. PubMed ID: 19549403
[TBL] [Abstract][Full Text] [Related]
12. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study.
Yamada K; Furusawa S; Saito K; Waga K; Koike T; Arimura H; Aoyagi A; Yamato H; Sakuma H; Tsunogake S
Leukemia; 1995 Jan; 9(1):10-4. PubMed ID: 7531259
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia complicating multiple myeloma: a case successfully treated with etoposide, thioguanine, and cytarabine.
Erikci AA; Ozturk A; Tekgunduz E; Sayan O
Clin Lymphoma Myeloma; 2009 Aug; 9(4):E14-5. PubMed ID: 19717372
[TBL] [Abstract][Full Text] [Related]
14. [Clinical efficacy of decitabine combined with modified CAG regimen for relapsed-refractory acute myeloid leukemia with AML1-ETO⁺].
Jing Y; Zhu CY; Zhang Q; Niu JH; Yang H; Liu SY; Zhu HY; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1245-50. PubMed ID: 25338566
[TBL] [Abstract][Full Text] [Related]
15. Successful Cytoreduction with CAG (cytarabine, Aclarubicin and G-CSF) Therapy in Refractory Acute Myelogenous Leukemia before Allogeneic Stem Cell Transplantation.
Murayama T; Imoto S; Gomyo H; Mizuno I; Kajimoto K; Sugimoto T; Tobinai K; Koizumi T
Hematology; 2001; 6(6):381-5. PubMed ID: 27405694
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia.
Li J; Chen Y; Zhu Y; Zhou J; Xu Y; Li Y; Yu K; Pan L; Wang J; Ding J; Gu J; Zhou S; Shi J; Hong M; Xu J; Pan L; Duan L; Zhang R; Zhang S; Zhu H; Lu H; Liu P; Qiu H; Wu H; Qian S
Oncotarget; 2015 Mar; 6(8):6448-58. PubMed ID: 25749041
[TBL] [Abstract][Full Text] [Related]
18. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients.
Li JM; Shen Y; Wu DP; Liang H; Jin J; Chen FY; Song YP; Song EY; Qiu XF; Hou M; Qiu ZC; Shen ZX
Int J Hematol; 2005 Jul; 82(1):48-54. PubMed ID: 16105759
[TBL] [Abstract][Full Text] [Related]
19. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia.
Suzushima H; Wada N; Yamasaki H; Eto K; Shimomura T; Kugimiya MH; Horikawa K; Nishimura S; Tsuda H; Mitsuya H; Asou N
Leuk Res; 2010 May; 34(5):610-4. PubMed ID: 19744710
[TBL] [Abstract][Full Text] [Related]
20. Complete remission following chemotherapy with low-dose cytosine arabinoside and macrophage colony-stimulating factor/granulocyte colony-stimulating factor in a patient with relapsed acute myeloid leukemia after stem cell transplantation.
Okada K; Higashiyama A; Takahata M; Onozawa M; Kahata K; Ando S; Tanaka J; Hashino S; Imamura M
Intern Med; 2012; 51(20):2937-41. PubMed ID: 23064572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
